-transparent.png){kind=logo}
The "vasoconstrictor" effect of dermally applicated steroids is a widely used parameter when determining the potency of glucocorticoids. A similar effect on the nasal mucosa has been suggested as providing an explanation for the clinical effect of topically administered glucocorticoids in the treatment of nasal disorders such as allergic and vasomotor rhinitis. The recently described 133Xe wash-out method was used for the purpose of blood flow determination in 11 healthy subjects. In a randomized double-blind cross-over study, the effect of topically administered budesonide, a non-halogenated glucocorticoid, for 1 week was compared with that of placebo. No difference was found to occur in the mucosal blood flow after the administration of budesonide, as compared with placebo. It seems likely that a more complex activity than vasoconstriction is responsible for the clinical effect in the treatment of nasal disorders, and further research is required in order to clarify this issue.
M Bende, and
N Lindqvist, and
U Pipkorn
January 1975,
Acta medica Academiae Scientiarum Hungaricae,
M Bende, and
N Lindqvist, and
U Pipkorn
January 1984,
Current medical research and opinion,
M Bende, and
N Lindqvist, and
U Pipkorn
January 1966,
Nephron,
M Bende, and
N Lindqvist, and
U Pipkorn
July 1978,
Nuklearmedizin. Nuclear medicine,
M Bende, and
N Lindqvist, and
U Pipkorn
November 1976,
Pflugers Archiv : European journal of physiology,
M Bende, and
N Lindqvist, and
U Pipkorn
March 2001,
Rhinology,
M Bende, and
N Lindqvist, and
U Pipkorn
January 1991,
Archives of oral biology,
M Bende, and
N Lindqvist, and
U Pipkorn
June 1965,
Pflugers Archiv fur die gesamte Physiologie des Menschen und der Tiere,
M Bende, and
N Lindqvist, and
U Pipkorn
October 1987,
International journal of oral and maxillofacial surgery,
M Bende, and
N Lindqvist, and
U Pipkorn
September 1992,
The Journal of Nihon University School of Dentistry,
